BSP Receives US Approval for Second Patent
BSP, an Israeli start-up company developing and marketing systems for early stage non-invasive diagnosis and monitoring of ischemic heart disease through biological signal processing, announced that it has received US notification of issuance for a second patent which reinforces its original technology. BSP's flagship product, the HyperQTM stress System, enables early stage non-invasive diagnosis and monitoring of ischemic heart disease in large populations by analysis and processing of ECG signals.
The title of the patent is "Apparatus and Method for Efficient Representation of Periodic and Nearly Periodic Signals for Analysis" and its patent number is: US Patent No. 7,239,988. This patent provides a new method for displaying periodic or nearly periodic biological signals, and in particular the HyperQTM signals. The new readout method provides the clinician with an easy and efficient diagnostic tool for diagnosing ischemic heart diseases while displaying a full Stress Test results on a single page.
Other news from the department research and development
![Newsletter](https://img.chemie.de/assets/bionity/images/newsletter.png)
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.